香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局（「國家藥監局」）有關氨茶鹼片（100mg）的藥品生產 註冊批件，屬於化學藥品第3類，視同通過一致性評價，是國內企業第三家獲批。氨茶鹼片主要 用於支氣管哮喘、喘息型支氣管炎、阻塞性肺氣腫等緩解喘息症狀，也可用於治療心源性肺水 腫引起的哮喘。本集團的氨茶鹼原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 董事局亦欣然公告，本集團已取得國家藥監局有關鹽酸丙卡特羅吸入溶液(0.5ml：50μg)及注射 用丁二磺酸腺苷蛋氨酸(0.5g)的藥品生產註冊批件，分別屬於化學藥品第3類及第4類，視同通 過一致性評價。鹽酸丙卡特羅吸入溶液主要用於緩解支氣管哮喘、慢性支氣管炎及肺氣腫以氣 流受限為基礎的各種症狀。注射用丁二磺酸腺苷蛋氨酸主要用於治療肝硬化前和肝 ...

Core Viewpoint - The recent increase in shareholding by Kelun Pharmaceutical in Shijiazhuang Yiling Pharmaceutical reflects a strategic move amidst declining profits for both companies, indicating a survival strategy rather than expansion [1][3]. Group 1: Financial Performance - Kelun Pharmaceutical's net profit for the first three quarters of 2025 plummeted by 51.41% to 1.201 billion yuan, while Shijiazhuang Yiling's net profit dropped by 58.7% to 283.5 million Hong Kong dollars [1][2]. - The total revenue for Kelun in the same period was 13.277 billion yuan, down 20.92% year-on-year [2]. - The decline in net profit for Kelun was significantly influenced by the poor performance of its joint venture with Shijiazhuang Yiling, which saw a 38.39% decrease in investment income [7]. Group 2: Strategic Moves - The increase to a 23.03% stake in Shijiazhuang Yiling allows Kelun to enhance its influence while avoiding the 30% threshold for mandatory takeover bids, showcasing a calculated approach to capital management [3]. - The long-term relationship between Kelun and Shijiazhuang Yiling has evolved from competition to cooperation, with both companies forming a "triangle alliance" to stabilize prices and avoid destructive competition [5][4]. - The collaboration includes joint procurement and sales agreements, which help mitigate the impact of price pressures in the intravenous infusion market [5]. Group 3: Market Challenges - The intravenous infusion market is facing significant challenges, including regulatory pressures and price reductions due to centralized procurement, leading to a 19.65% decline in sales revenue for Kelun's core infusion business [8][9]. - The company's traditional business is under severe pressure, while new business segments have not yet compensated for the losses, creating a transitional struggle [10]. Group 4: Marketing and Public Perception - The controversial marketing campaign led by Chairman Liu Gexin, which involved him promoting a health product, reflects the company's anxiety over declining performance and the need for innovative marketing strategies [11][12]. - Despite the backlash, the campaign generated significant revenue, indicating a potential shift towards the health product market, which is projected to be worth 12.3 trillion yuan [12][15]. - The strategic partnership with the Thailand Miracle Life Foundation aims to enhance pharmaceutical innovation and expand into the health product sector, further indicating Kelun's commitment to diversifying its business model [15].

吲哚布芬片主要用于治疗动脉硬化引起的缺血性心血管病变、缺血性脑血管病变及静脉血栓形成，也可 用于血液透析时预防血栓形成。 （原标题：石四药集团(02005)：取得吲哚布芬片(0.2g)药品生产注册批件） 智通财经APP讯，石四药集团(02005)发布公告，集团已取得中国国家药品监督管理局有关吲哚布芬片 (0.2g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。 ...

Core Viewpoint - The company has obtained the drug production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The drug can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company has obtained the production registration approval for Indobufene Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1: Product Information - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The drug can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has obtained the production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company has obtained the production registration approval for Indobufen Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - The Indobufen Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The tablets can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has obtained the production registration approval for Indobufene Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - The Indobufene Tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The tablets can also be used to prevent thrombosis during hemodialysis [1]

石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關吲哚布芬片(0.2g)的藥品生產註冊批件，屬於化學 藥品第3類，視同通過一致性評價。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 吲哚布芬片主要用於治療動脈硬化引起的缺血性心血管病變、缺血性腦血管病變及靜脈血栓形 成，也可用於血液透析時預防血栓形成。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十一月十四日 ...

Core Insights - Sichuan Kelun Pharmaceutical Co., Ltd. increased its stake in Shijiazhuang Fourth Pharmaceutical Co., Ltd. by acquiring 1,128,000 shares at an average price of HKD 3.0978 per share, totaling approximately HKD 3.4943 million [1] Group 1 - The shareholding of Sichuan Kelun Pharmaceutical increased from 22.99% to 23.03% following the acquisition [1][2] - The total number of shares held by Sichuan Kelun Pharmaceutical after the purchase is 679,558,000 [1][2]